…
Halberd Corporation, a biotech company, develops treatments for neurodegenerative diseases. It offers treatments for post traumatic stress disorder/chronic traumatic encephalopathy, Alzheimer's and Parkinson's disease, cancer, blood-borne, and cerebrospinal fluid related diseases. The company was incorporated in 2009 and is based in Jackson Center, Pennsylvania.
Source: TradingView
The charts and visual representations are sourced from TradingView through embedded widgets. For any issues with chart display, please visit the TradingView website
A unique technical analysis driven score developed by Kalkine showing momentum in stock prices based on select technical indicators identified.
Tykhe Corp (HALB.US) is an OTC Pink-listed company for which comprehensive public disclosures and audited filings are scarce, so its core business activities are not clearly documented in major regulatory sources. Because of that lack of transparency, long-term growth drivers are uncertain and the stock may appeal primarily to speculative investors seeking exposure to an early-stage or thinly traded issuer.
Note: The summary and risk score provided above is created by AI and should not be construed as a recommendation of Kalkine.
| Breakdown | 2025-07-31 | 2024-07-31 | 2023-07-31 | 2022-07-31 | 2021-07-31 |
|---|---|---|---|---|---|
| Type | yearly | yearly | yearly | yearly | yearly |
| Date | 2025-07-31 | 2024-07-31 | 2023-07-31 | 2022-07-31 | 2021-07-31 |
| Income before tax | -0.02M | -0.08M | -0.45M | -1.62M | - |
| Net income | -0.02M | -0.08M | -0.45M | -1.62M | - |
| Selling general administrative | - | - | 0.15M | 0.71M | - |
| Gross profit | -0.00M | -0.00M | 0.00M | 0.01M | - |
| Reconciled depreciation | - | - | 0.00M | 0.00M | - |
| Ebit | -0.02M | -0.08M | -0.45M | -1.62M | -0.94M |
| Ebitda | -0.02M | -0.07M | -0.45M | -1.62M | - |
| Depreciation and amortization | 0.00M | 0.00M | 0.00M | 0.00M | - |
| Operating income | -0.02M | -0.08M | -0.45M | -1.62M | - |
| Other operating expenses | 0.02M | 0.08M | 0.45M | 1.63M | - |
| Interest expense | 0.00M | 0.00M | 0.01M | 0.01M | 0.00M |
| Net interest income | - | - | -0.01M | -0.01M | - |
| Total revenue | - | 0.00M | 0.00M | 0.01M | - |
| Total operating expenses | 0.02M | 0.07M | 0.45M | 1.63M | - |
| Cost of revenue | 0.00M | 0.00M | 0.00M | 0.00M | - |
| Total other income expense net | -0.00M | -0.00M | -0.01M | -0.01M | - |
| Net income from continuing ops | - | - | -0.45M | -1.62M | - |
| Net income applicable to common shares | - | - | - | - | -0.96M |
| Breakdown | 2025-07-31 | 2024-07-31 | 2023-07-31 | 2022-07-31 | 2021-07-31 |
|---|---|---|---|---|---|
| Type | yearly | yearly | yearly | yearly | yearly |
| Date | 2025-07-31 | 2024-07-31 | 2023-07-31 | 2022-07-31 | 2021-07-31 |
| Total assets | 0.00M | 0.01M | 0.01M | 0.02M | - |
| Other current assets | 0.00M | 0.00M | - | - | - |
| Total liab | 0.92M | 0.73M | 0.94M | 0.75M | - |
| Total stockholder equity | -0.91M | -0.72M | -0.93M | -0.73M | - |
| Other current liab | 0.20M | 0.19M | 0.21M | 0.22M | 0.22M |
| Common stock | 0.06M | 0.06M | 0.06M | 0.05M | 0.05M |
| Capital stock | - | - | 0.06M | 0.05M | - |
| Retained earnings | -7.00M | -6.98M | -6.90M | -6.44M | -4.82M |
| Cash | - | 0.01M | 0.01M | 0.01M | - |
| Total current liabilities | 0.77M | 0.58M | 0.79M | 0.60M | 0.40M |
| Net debt | 0.15M | 0.14M | 0.14M | 0.14M | - |
| Short long term debt total | 0.15M | 0.15M | 0.15M | 0.15M | - |
| Other stockholder equity | 6.02M | 6.20M | 5.91M | 5.66M | - |
| Property plant equipment | - | - | - | - | 0.00M |
| Total current assets | 0.00M | 0.01M | 0.01M | 0.01M | 0.06M |
| Net tangible assets | - | - | - | - | -0.49M |
| Long term debt | - | - | 0.15M | 0.15M | - |
| Accounts payable | 0.57M | 0.39M | 0.58M | 0.38M | 0.18M |
| Non currrent assets other | - | 0.00M | - | - | - |
| Non current assets total | 0.00M | 0.00M | 0.00M | 0.00M | - |
| Breakdown | 2024-07-31 | 2023-07-31 | 2022-07-31 | 2021-07-31 | 2020-07-31 |
|---|---|---|---|---|---|
| Type | yearly | yearly | yearly | yearly | yearly |
| Date | 2024-07-31 | 2023-07-31 | 2022-07-31 | 2021-07-31 | 2020-07-31 |
| Investments | - | 0.00M | -0.00M | - | - |
| Change to liabilities | - | - | - | 0.17M | 0.01M |
| Total cashflows from investing activities | - | - | - | -0.00M | -0.00M |
| Net borrowings | - | - | - | 0.15M | 0.15M |
| Total cash from financing activities | 0.05M | 0.24M | 0.89M | 0.82M | 0.04M |
| Change to operating activities | - | - | - | -0.01M | -0.00M |
| Net income | -0.08M | -0.45M | -1.62M | -0.96M | -1.65M |
| Change in cash | -0.00M | -0.00M | -0.03M | 0.04M | 0.00M |
| Begin period cash flow | 0.01M | 0.01M | 0.04M | - | - |
| End period cash flow | 0.01M | 0.01M | 0.01M | 0.04M | - |
| Total cash from operating activities | -0.05M | -0.24M | -0.92M | -0.79M | -0.04M |
| Issuance of capital stock | - | 0.24M | 0.89M | - | - |
| Depreciation | 0.00M | 0.00M | 0.00M | - | - |
| Other cashflows from financing activities | - | - | -0.00M | - | - |
| Change to netincome | - | - | - | 0.02M | 1.60M |
| Capital expenditures | 0.00M | 0.00M | 0.00M | 0.00M | 0.00M |
| Change in working capital | 0.03M | 0.21M | 0.22M | - | - |
| Other non cash items | - | - | 0.48M | - | - |
| Free cash flow | -0.05M | -0.24M | -0.92M | - | - |
Sector: Healthcare Industry: Biotechnology
|
Stock Name
|
Change
(USD) |
Price
(USD) |
Trailing
PE (x) |
Forward
PE (x) |
Price Sales
TTM (x) |
Price to Book Value (x)
|
Enterprise Value
to Revenue (x) |
Enterprise Value
to EBITDA (x) |
|---|---|---|---|---|---|---|---|---|
| HALB Tykhe Corp |
0.00 14.29% |
0.00 | - | - | 101.93 | 16.90 | 472.90 | -3.50 |
| NVO Novo Nordisk A/S |
-0.54 1.32% |
40.55 | 41.58 | 31.15 | 2.13 | 32.99 | 2.11 | 4.70 |
| VRTX Vertex Pharmaceuticals Inc |
-2.37 0.43% |
544.66 | 30.22 | 24.27 | 10.36 | 6.50 | 9.99 | 24.66 |
| REGN Regeneron Pharmaceuticals Inc |
-2.77 0.29% |
956.64 | 29.07 | 20.12 | 7.57 | 3.82 | 6.95 | 19.42 |
| ARGNF argenx SE |
- -% |
900.30 | 45.77 | 31.25 | 13.84 | 7.12 | 11.38 | 36.06 |
Halberd Corporation, a biotech company, develops treatments for neurodegenerative diseases. It offers treatments for post traumatic stress disorder/chronic traumatic encephalopathy, Alzheimer's and Parkinson's disease, cancer, blood-borne, and cerebrospinal fluid related diseases. The company was incorporated in 2009 and is based in Jackson Center, Pennsylvania.
| Name | Title | Year Born |
|---|---|---|
| Mr. William A. Hartman | Pres, CEO & Chairman | 1942 |
| Mr. John S. Borza AVS, MBA, PE | COO & Director | 1954 |
| Ms. Heidi H. Carl | Director & Accounting Director | 1971 |
| Dr. Mitchell S. Felder M.D. | CTO & Member of the Scientific Advisory Board | 1954 |
| Dr. Patricio F. Reyes FAAN, M.D. | Chief Mechanical Officer & Member of the Scientific Advisory Board | 1947 |
| Mr. William A. Hartman | President, CEO & Chairman | 1942 |
Disclaimer - (*)This information, including any data, is sourced from Unicorn Data Services SAS, trading as EOD Historical Data (“EODHD”) on an ‘as is’ basis, using their API. We cannot guarantee the completeness or validity of the information and data provided on this page, as well as via the API. In some cases, the data may include analyst ratings or recommendations sourced through the EODHD API, which are intended solely for general information purposes.
This information does not consider your personal objectives, financial situation, or needs. Kalkine is not liable for any errors or omissions in the information provided or for any actions taken in reliance on it. You should seek advice from a financial adviser, stockbroker or other professional adviser (including taxation and legal advice) as necessary before acting on this information.